Core Viewpoint - The stock price of Innovent Biologics (01801) experienced a decline of 5.37% on August 11, trading at 86.35 CNY per share with a transaction volume of 999.3 million CNY [1] Company Overview - Innovent Biologics focuses on the research, development, production, and sales of innovative drugs targeting major diseases such as tumors, autoimmune diseases, metabolic disorders, and ophthalmology [1] - The company has successfully launched 10 products, with 4 products currently under review and 4 new drug molecules in Phase III or pivotal clinical studies. Additionally, 18 new drug candidates are in clinical research [1] Financial Performance - As of the 2024 annual report, Innovent Biologics reported total revenue of 9.422 billion CNY and a net profit of -94.631 million CNY [1] - The company's patient assistance program has benefited over 170,000 patients, with a total drug donation value of 3.4 billion CNY [1] Upcoming Events - Innovent Biologics is scheduled to disclose its interim report for the fiscal year 2025 on August 27 [1]
信达生物(01801)下跌5.37%，报86.35元/股